Tag Archives: MRK

Hot Heal Care Stocks To Buy For 2019

PCM (NASDAQ: PCMI) and Insight Enterprises (NASDAQ:NSIT) are both small-cap consumer discretionary companies, but which is the better stock? We will compare the two businesses based on the strength of their institutional ownership, analyst recommendations, profitability, earnings, valuation, risk and dividends.


Get PCM alerts:

This table compares PCM and Insight Enterprises’ net margins, return on equity and return on assets.

Net Margins Return on Equity Return on Assets
PCM 0.08% 11.19% 2.09%
Insight Enterprises 1.57% 15.75% 4.89%

Institutional and Insider Ownership

55.2% of PCM shares are owned by institutional investors. Comparatively, 97.1% of Insight Enterprises shares are owned by institutional investors. 24.0% of PCM shares are owned by insiders. Comparatively, 1.8% of Insight Enterprises shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock will outperform the market over the long term.

Hot Heal Care Stocks To Buy For 2019: Stryker Corporation(SYK)

Advisors’ Opinion:

  • [By Logan Wallace]

    COPYRIGHT VIOLATION NOTICE: “Stryker Co. (SYK) Holdings Lifted by Daiwa Securities Group Inc.” was posted by Ticker Report and is owned by of Ticker Report. If you are viewing this article on another site, it was copied illegally and republished in violation of US & international trademark and copyright law. The correct version of this article can be viewed at www.tickerreport.com/banking-finance/4150560/stryker-co-syk-holdings-lifted-by-daiwa-securities-group-inc.html.

  • [By Dan Caplinger]

    Finally, shares of Boston Scientific sank 6%. The medical device maker had jumped earlier in the week on reports that it might receive a takeover bid from industry peer Stryker (NYSE:SYK). Yet today, Stryker denied that it had been in acquisition talks with Boston Scientific, throwing cold water on the idea. With the downward push, Boston Scientific is now back to where the stock started the week before the reports surfaced in the first place. Boston Scientific will now apparently have to make the most of its own opportunities in the medical device space — at least unless another potential buyer comes around.

  • [By Logan Wallace]

    US Bancorp DE grew its stake in Stryker Co. (NYSE:SYK) by 2.4% in the 1st quarter, according to its most recent filing with the Securities and Exchange Commission. The institutional investor owned 154,942 shares of the medical technology company’s stock after purchasing an additional 3,643 shares during the quarter. US Bancorp DE’s holdings in Stryker were worth $24,935,000 at the end of the most recent quarter.

  • [By Ethan Ryder]

    Stryker (NYSE:SYK) had its hold rating reissued by analysts at Needham & Company LLC. The analysts wrote, “SYK is acquiring Invuity (IVTY) for $7.40 per share (a 29% premium) or ~$190M of cash which is 3.4x consensus 2019E sales (vs. 6.4x EV/2019E sales for its medical supplies peers). IVTY makes disposable lighted instruments which increase visibility during minimally invasive surgical (MIS) procedures. We believe IVTY fits well with SYK’s Instruments business and note that IVTY’s products are applicable to a large number of surgical procedures. While the deal may be slightly dilutive in 2019, we believe that SYK can absorb this and still deliver on its 9%+ EPS growth target. And the deal should start to become increasingly accretive in 2020 and beyond.””

  • [By Steve Symington]

    Boston Scientific stock rose 7.4% today after The Wall Street Journal reported (subscription required) that the medical device specialist has received a takeover bid from rival Stryker Corporation (NYSE:SYK). Shares of Stryker simultaneously declined more than 5% on the news.

Hot Heal Care Stocks To Buy For 2019: Treehouse Foods, Inc.(THS)

Advisors’ Opinion:

  • [By Joseph Griffin]

    Get a free copy of the Zacks research report on TreeHouse Foods (THS)

    For more information about research offerings from Zacks Investment Research, visit Zacks.com

  • [By Ethan Ryder]

    Get a free copy of the Zacks research report on TreeHouse Foods (THS)

    For more information about research offerings from Zacks Investment Research, visit Zacks.com

  • [By Lisa Levin] Gainers
    Euro Tech Holdings Company Limited (NASDAQ: CLWT) surged 73.3 percent to $3.90.
    Integrated Media Technology Limited (NASDAQ: IMTE) shares gained 51 percent to $33.1365. The nano-cap low-float stock skyrocketed over 1,300 percent on Wednesday on no company specific news which would support the surge. The move higher is consistent with what was seen in other low-float stocks over the past few months.
    Monaker Group, Inc. (NASDAQ: MKGI) shares jumped 34 percent to $3.00.
    Sharing Economy International Inc. (NASDAQ: SEII) shares rose 28.2 percent to $4.51 after gaining 9.32 percent on Wednesday.
    STAAR Surgical Company (NASDAQ: STAA) shares jumped 27.8 percent to $21.40 after reporting upbeat Q1 results.
    Boxlight Corporation (NASDAQ: BOXL) rose 20.5 percent to $8.920 after climbing 107.87 percent on Wednesday.
    Xspand Products Lab Inc (NASDAQ: XSPL) gained 19.5 percent to $ 5.97. Xspand Products priced its IPO at $5 per share.
    YRC Worldwide Inc. (NASDAQ: YRCW) rose 18.9 percent to $10.035 following upbeat quarterly earnings.
    ENDRA Life Sciences Inc. (NASDAQ: NDRA) gained 18.3 percent to $3.0177. ENDRA Life Sciences is expected to report Q1 results on May 15.
    MYR Group Inc. (NASDAQ: MYRG) rose 18.1 percent to $35.85 after the company posted strong Q1 earnings.
    Rudolph Technologies, Inc. (NASDAQ: RTEC) shares jumped 16 percent to $30.75 following upbeat quarterly earnings.
    TTM Technologies, Inc. (NASDAQ: TTMI) gained 13.7 percent to $16.53 after reporting Q1 results.
    Insight Enterprises, Inc. (NASDAQ: NSIT) shares surged 12 percent to $40.06 following better-than-expected Q1 earnings.
    TreeHouse Foods, Inc. (NYSE: THS) rose 11.8 percent to $40.93 following Q1 results.
    Engility Holdings, Inc. (NYSE: EGL) surged 11.2 percent to $27.36. Engility reported upbeat quarterly earnings.
    Synalloy Corporation (NASDAQ: SYNL) rose 10.7 percent to $19.10 following Q1 results.
    Logitech International S.A. (NASDAQ: LOGI)
  • [By Joseph Griffin]

    TechShares (THS) is a distributed proof-of-stake (dPOS) coin that uses the DPoS hashing algorithm. It was first traded on May 28th, 2016. TechShares’ total supply is 646,359,158 coins. The official website for TechShares is www.techsharescommunity.com.

Hot Heal Care Stocks To Buy For 2019: Merck & Company, Inc.(MRK)

Advisors’ Opinion:

  • [By Jon C. Ogg]

    Merck & Co. Inc. (NYSE: MRK) and Pfizer Inc. (NYSE: PFE) were named in an August 3 Merrill Lynch report in which the firm rebalanced its income portfolio. It increased its portfolio position in Merck to 3.0% from 2.0% and in Pfizer to 3.0% from 2.5%. AbbVie Inc. (NYSE: ABBV) and Amgen Inc. (NASDAQ: AMGN) were also kept in the portfolio, with weights of 1.5% and 2.0%, respectively.

  • [By Chris Lange]

    Merck & Co. Inc. (NYSE: MRK) has a PDUFA target action date of October 6, for its Gardasil 9 (human papillomavirus 9-valent vaccine, recombinant), the company’s 9-valent HPV vaccine. The application is seeking approval for an expanded age indication for Gardasil 9 for use in women and men ages 27 to 45 for the prevention of certain cancers and diseases caused by the nine HPV types covered by the vaccine.

  • [By ]

    1. Merck (NYSE: MRK)
    This drug company is currently yielding 3.3% and is trading lower by over 6% in the last year. A low payout ratio of 47 combined with debt to the total capital ratio of just over 36% means Merck should be able to continue paying stable dividends into the future.

  • [By Joseph Griffin]

    Gratus Capital LLC lifted its holdings in Merck & Co., Inc. (NYSE:MRK) by 108.7% during the 1st quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor owned 7,678 shares of the company’s stock after acquiring an additional 3,999 shares during the quarter. Gratus Capital LLC’s holdings in Merck & Co., Inc. were worth $418,000 at the end of the most recent reporting period.

  • [By Max Byerly]

    Cfra set a €89.00 ($103.49) price objective on Merck KGaA (FRA:MRK) in a research report sent to investors on Friday. The brokerage currently has a neutral rating on the healthcare company’s stock.

Hot Small Cap Stocks To Own Right Now

Its finally official: Up and coming small cap Cannabidiol (CBD) stock MyCloudz, Inc (OTC: MYYZ) is now officially Gridiron BioNutrients (OTC: GMVP) as the Company confirmed its name and ticker change effective December 19th. Gridiron BioNutrients is a nutraceutical innovator specializing in cannabidiol health health and wellness products founded by Darren Long, a former NFL tight-end and 3x All American College Football Player who became an advocate of health and proper nutrition as a result of the symptoms from Chronic Traumatic Encephalopathy (CTE) or brain concussions. Gridiron BioNutrients’ current innovative CBD products include Gridiron MVP™ water, Gridiron MVP™ concentrate, Gridiron CBD H2O Probiotics™ water, Gridiron Premium Hemp Salve, Gridiron Premium Hemp Oil and Gridiron Premium Hemp Oil Capsules plus the Company plans to roll-out additional products over the next twelve months.

Hot Small Cap Stocks To Own Right Now: Taiwan Semiconductor Manufacturing Company Ltd.(TSM)

Advisors’ Opinion:

  • [By Ashraf Eassa]

    Although chip giant Intel (NASDAQ:INTC) manufactures most of its products internally using its own manufacturing process technologies, the company still outsources the production of some products to its key rival, Taiwan Semiconductor Manufacturing Company (NYSE:TSM). 

  • [By Ashraf Eassa]

    Qualcomm didn’t name the manufacturer of this now-sampling platform, but since Taiwan Semiconductor Manufacturing Company (NYSE:TSM) (TSMC) is the only company that’s currently mass-producing chips on a 7-nanometer technology, it’s safe to say that TSMC is building it.

  • [By ]

    Taiwan Semiconductor Manufacturing Co. (TSM) announced first-quarter financial results Thursday. The company, which is the world’s largest independent semiconductor maker, tallied about $8.5 billion in sales revenue during the quarter, up 6.1% from a year earlier. President and Co-CEO C.C. Wei said on a conference call, “These results were mainly driven by strong demand from high performance computing such as cryptocurrency mining.” Fellow Co-CEO Mark Liu added, “We see very strong demand in the first quarter from cryptocurrencies. During the second quarter, while we do see some weakness in the 28mm chip, the [demand for] the rest of the technology is still very strong on cryptocurrency.”

Hot Small Cap Stocks To Own Right Now: Merck & Company, Inc.(MRK)

Advisors’ Opinion:

  • [By Keith Speights]

    First, BMS won Food and Drug Administration (FDA) approval for a new dosing schedule for Opdivo on March 6. This change allows physicians to administer Opdivo to patients every four weeks instead of every two weeks for most of the approved indications for the drug. In addition, Opdivo was approved for a shorter 30-minute infusion for all approved indications. Opdivo now enjoys an advantage related to patient convenience that Merck’s (NYSE:MRK) Keytruda doesn’t.

  • [By Shane Hupp]

    MARK.SPACE (CURRENCY:MRK) traded 10.1% lower against the US dollar during the 1 day period ending at 21:00 PM ET on June 9th. In the last week, MARK.SPACE has traded up 0.5% against the US dollar. One MARK.SPACE token can currently be bought for $0.0425 or 0.00000581 BTC on popular exchanges including COSS and BTC-Alpha. MARK.SPACE has a market capitalization of $10.01 million and $572,635.00 worth of MARK.SPACE was traded on exchanges in the last day.

  • [By Cory Renauer]

    From a commercial standpoint, the most successful class of drugs that help the immune system fight cancer are the PD-1 inhibitors. Opdivo, from Bristol-Myers Squibb (NYSE:BMY), and Keytruda, from Merck & Co. (NYSE:MRK), weren’t available a few years ago. But the pair will probably generate a combined $12 billion in sales this year.

Hot Small Cap Stocks To Own Right Now: Capstead Mortgage Corporation(CMO)

Advisors’ Opinion:

  • [By Logan Wallace]

    Capstead Mortgage (NYSE:CMO) was downgraded by investment analysts at ValuEngine from a “hold” rating to a “sell” rating in a research report issued on Wednesday.

General Electric, DowDuPont Lead the Dow Higher Wednesday

May 9, 2018: Markets opened higher Wednesday before dipping below the break-even line in the late morning and then taking off for a couple of hours in the afternoon to put equities on track for a decent daily gain. Energy stocks rose mostly steadily as the U.S. rejection of the Iran deal is widely believed to be quite bullish for oil prices and everything connected to black gold. Interestingly, both the dollar and 10-year Treasuries posted solid gains today as well.

WTI crude oil for June delivery settled at $71.14 a barrel, up 3% for the day after a bullish inventory report to go with the news about the Iran nuclear deal. June gold dipped less than 0.1% on the day to settle at $1,313.00. Equities were headed for a higher close about 10 minutes before the bell as the Dow traded up 0.61% for the day, the S&P 500 traded up 0.86%, and the Nasdaq Composite traded up 0.91%.

Bitcoin futures (XBTK8) for May delivery traded at $9,270, up about 0.5% on the CBOE after opening at $9,235 this morning. The trading range today was $8,945 to $9,370.

The Dow stock posting the largest daily percentage gain ahead of the close Wednesday was DowDuPont Inc. (NYSE: DWDP) which traded up 2.83% at $66.05. The stock’s 52-week range is $59.29 to $77.08. Volume was about 20% below the daily average of around 9 million shares. The company had no specific news.

General Electric Co. (NYSE: GE) traded up 2.56% at $14.64. The stock’s 52-week range is $12.73 to $29.47. Volume was about half the daily average of around 76.3 million. The company had no specific news.

Exxon Mobil Corp. (NYSE: XOM) traded up 2.29% at $79.88 in a 52-week range of $72.16 to $89.30. Volume was about 15 below the daily average of 15.7 million. The company had no specific news, but oil prices shot up.

Merck & Co. Inc. (NYSE: MRK) traded up 2.03% at $57.91. The stock’s 52-week range is $52.83 to $66.41. Volume was about half the daily average of around 12 million shares. The company had no specific news.

Of the Dow stocks, 22 are on track to close higher Wednesday and 8 are set to close lower.

ALSO READ: Merrill Lynch Makes Big Changes to Top-Performing Growth Portfolio

Reader Inquiry: Is Recent Weakness In Array BioPharma Warranted?

Shares of Array BioPharma (ARRY) have risen by 57% since my original article was published last August (at one point they麓d nearly doubled before the recent pullback).

The stock was later added as one of our 20 holdings in the Core Biotech model account and is currently our biggest loser, in the red by 21%.

In my latest update piece from December, I restated the following keys to the bullish thesis:

A compelling rationale for the approval of the combination of binimetinib and encorafenib for the treatment of patients with BRAF-mutant advanced, unresectable or metastatic melanoma, supported by strong data from the pivotal COLUMBUS trial. Large market opportunities targeted, an example being the global melanoma market for MEK/BRAF inhibitors of over $1 billion. The company麓s vast pipeline and past history of advantageously monetizing its noncore assets, just as had occurred with the Amgen (NASDAQ:AMGN) drug development deal for autoimmune disorders with the larger company footing the bill. Other positive prior pacts included collaborations with Merck (NYSE:MRK) and Bristol-Myers Squibb (NYSE:BMY) along with monetization of rights in Japan and South Korea. Chart

Figure 1: ARRY daily advanced chart (source: Finviz)

Figure 2: ARRY 15 minute advanced chart (source: Finviz)

When looking at charts, clarity often comes from taking a look at distinct time frames in order to determine important technical levels and get a feel for what is going on. After positive news in late January the stock hit highs at over $18, but from there has fallen victim to lower volume selling and is trying to find a bottom at $13.

Reader Inquiry

In the marketplace service ROTY (Runners of the Year), we search for stocks that are attractive across multiple time frames with high % upside potential within the near to medium term. Catalyst ideas typically have upcoming material events (such as clinical results reading out or regulatory action date) that could push shares significantly higher- on the other hand, revaluation ideas involve stocks where the core business (or core assets) and recent events have not been fully factored into the share price AND future appreciation is expected.

Figure 3: Operational summary (source: Q2 slides)

In the case of Array BioPharma, I麓ve received a few inquiries from readers who hold shares and have been worried by the recent slide in the stock price. While in Live Chat I simply stated the thesis remains on track, I麓ve seen enough concern surrounding the name that it merits revisiting. Currently my plan for the Core Biotech account is to continue holding our full position in the stock with a multi-year time frame ahead, but it麓s important to continually reassess the thesis for all of our holdings in light of recent developments and make changes as necessary.

Recent Developments

The company started off 2018 with a big step forward when they announced updated results from the 30 patient safety lead-in of the phase 3 BEACON CRC study evaluating the triplet combination of encorafenib, binimetinib and cetuximab in patients with BRAF-mutant metastatic colorectal cancer whose disease has progressed after one or two prior regimens. Presented at ASCO GI, patients with the BRAFV600E mutation experienced median progression free survival of 8 months with overall response rate of 48% (including 3 patients who achieved complete responses). For patients who received only one prior line of therapy ORR increased to 62% (n=16). As for the safety profile, two patients discontinued treatment due to adverse events (only 1 related to study drug) with most common grade 3 of 4 adverse events (in at least 10% of patinets) being fatigue, urinary tract infection, increased aspartate aminotransferase and increased blood creatine kinase.

Figure 4: BEACON CRC Safety Lead In Compared to Historical Benchmarks (source: Q2 slides)

To put this into context, readers should pay close attention to remarks and optimism voiced by Scott Kopetz, M.D., Ph.D., FACP, Associate Professor, Department of Gastrointestinal Medical Oncology, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center (my emphasis in bold):

We are very excited about these safety lead-in results, which show both an unprecedented progression-free survival and overall response rate in patients with BRAFV600-mutant colorectal cancer. To put these data in context, the observed median progression-free survival of 8 months exceeds historical benchmarks of approximately 2 months for median progression-free survival, and 4 to 6 months for median overall survival, with current standards of care in this patient population. These results demonstrate the potential of the triplet combination to benefit this population of patients who currently have very limited effective treatment options.

In late March the company announced that detailed results from the pivotal phase 3 COLOMBUS trial for the treatment of patients with BRAF-mutant advanced, unresectable or metastatic melanoma were published in The Lancet Oncology. As noted before, median PFS for patients treated with encorafenib plus binimetinib of 14.9 months compared very favorably to 7.3 months for patients treated with vemurafenib.

Other Information

For the second quarter the company reported cash and equivalents of $420 million, which compared favorably to net loss of $34.1 million. Research and development expenses rose slightly to $42.6 million, while revenue increased substantially to $42.2 million (due in part to $7.9 million deferral of the Asahi Kasei Pharma upfront payment plus higher Novartis reimbursement revenue).

Immuno-oncology efforts are not getting much attention, even as trials with collaborators continue to make headway. A study run in conjunction with Bristol-Myers Squibb (sponsored by Array but supported by both companies) is evaluating binimetinib in combination with anti-PD-1 asset nivolumab (with and without CTLA-4 antibody ipilimumab) in patients with advanced metastatic microsatellite stable CRC and the presence of a RAS mutation who have received one or two prior regimens. Merck (MRK) is sponsoring and funding a study evaluating binimetinib in combination with anti-PD-1 asset pembrolizumab with and without chemotherapy in patients with CRC whose tumors are not microsatellite instability-high. Pfizer (PFE) is sponsoring and funding a trial evaluating binimetinib, anti-PD-L1 asset avelumab and PARP inibitor talazoparib in several tumor types with an initial focus on non-small cell lung cancer and pancreatic cancer (to get underway in the third quarter). Keep in mind that none of these collaborations are exclusive, as management is keeping open its options for partnering (or better yet buyout).

Another detail that may have escaped some investors is that Array formed a wholly-owned subsidiary (Yarra Therapeutics) to develop drug candidates focused on rare diseases, including oral, selective p38 mitogen-activated protein kinase inhibitor ARRY-797. A phase 3 trial in patients with LMNA A/C-related dilated cardiomyopathy is getting underway.

As for upcoming catalysts of note, the main one is their June 30th PDUFA date where the FDA will hopefully give the thumbs up for use of the combination of encorafenib and binimetinib for the treatment of patients with BRAF-mutant advanced, unresectable or metastatic melanoma. Regulatory submissions are also being reviewed by the European Medicines Agency, Swiss Medicines Agency and Australian Therapeutic Goods Aministration.

As for institutional investors of note, BVF continues to add to its stake (over 8.6 million shares). Orbimed Advisors, Point 72 Asset Management, VenBio and others also own significant positions.

Final Thoughts

I continue to believe readers who are interested in the story and have done their due diligence should establish pilot positions in the near term or continue to add to their stakes, taking advantage of current weakness. As stated before, in the Core Biotech series we have a full position and will continue to hold it as the thesis remains clearly intact.

Risks to thesis include disappointing data for pivotal and early stage trials, clinical setbacks and dilution in late 2018 and beyond. Regulatory risk and competition with other approved BRAF/MEK inhibitors are also a key concern. While it would appear it has a strong liquidity position, the company has retained commercialization rights to the United States and will require significant resources for launching its clinical candidates if approved. Due to unmet needs in the indications being targeted and promising data, I am optimistic about market penetration and payer support while acknowledging the possibility of a slow or rocky start as a risk factor.

While I won麓t be adding this one to the ROTY Contenders List currently, I imagine it will continue to be discussed a good deal in Live Chat and a rebound in the near to medium term is quite possible.

Keep in mind that when a stock is selected for ROTY the corresponding article appears only to current subscribers, and for the purposes of due diligence subscribers are able to access all of my archived work (getting around the 10 day paywall).

Disclaimer: Commentary presented is NOT individualized investment advice. Opinions offered here are NOT personalized recommendations. Readers are expected to do their own due diligence or consult an investment professional if needed prior to making trades. Strategies discussed should not be mistaken for recommendations, and past performance may not be indicative of future results. Although I do my best to present factual research, I do not in any way guarantee the accuracy of the information I post. I reserve the right to make investment decisions on behalf of myself and affiliates regarding any security without notification except where it is required by law. Keep in mind that any opinion or position disclosed on this platform is subject to change at any moment as the thesis evolves. Investing in common stock can result in partial or total loss of capital. In other words, readers are expected to form their own trading plan, do their own research and take responsibility for their own actions. If they are not able or willing to do so, better to buy index funds or find a thoroughly vetted fee-only financial advisor to handle your account. I am in a collaborative relationship with The Biotech Forum/Bret Jensen.

Disclosure: I am/we are long ARRY.

I wrote this article myself, and it expresses my own opinions. I am not receiving compensation for it (other than from Seeking Alpha). I have no business relationship with any company whose stock is mentioned in this article.

Apple, McDonald’s, Pfizer and Other Dow Earnings Coming This Week

Most of the Dow Jones industrial index components have reported their latest quarterly reports, and overall the results have been solid. Yet the index is marginally lower than it was two weeks ago.

This week, five of the 30 Dow components are expected to share their results this week. The Dow has been subject to increased volatility since January, and some investors may have looked to the current earnings season to stabilize the index.

24/7 Wall St. has put together a preview of those Dow companies scheduled to report their quarterly results this week. Here, we have included the consensus earnings estimates from Thomson Reuters, as well as the stock price and trading history.

Also see our separate preview of some of the week’s other most anticipated earnings reports, including Alibaba, CVS and Tesla.

Be advised that the earnings and revenue estimates may change ahead of the formal reports, and some companies may change reporting dates as well.

McDonalds Corp. (NYSE: MCD) is set to report its most recent quarterly results first thing Monday morning. Analysts are looking for $1.67 in earnings per share (EPS) and $4.97 billion in revenue. Shares closed the week at $158.30, with a consensus price target of $185.54 and a 52-week trading range of $190.59 to $259.77.

Merck & Co. Inc. (NYSE: MRK) is expected to report its first-quarter results early Tuesday. The analysts consensus forecast is EPS of $1.00 on $10.10 billion in revenue. Shares were changing hands at $59.47 as last week came to a close. The consensus price target is $68.40, and the stock has a 52-week range of $52.83 to $66.41.

Pfizer Inc. (NYSE: PFE) will share its latest quarterly earnings before Tuesdays opening bell as well. The consensus estimates call for $0.75 in EPS and $13.15 billion in revenue. Shares ended last week at $37.00, in a 52-week range of $31.67 to $39.43. The consensus analyst target is $40.11.

Apple Inc. (NASDAQ: AAPL) is scheduled to share its quarterly report late on Tuesday. The consensus estimates are $2.69 in EPS on $60.98 billion in revenue. Shares were last seen at $162.32. The stock has a 52-week range of $142.20 to $183.50, and the consensus price target is $192.94.

And DowDuPont Inc. (NYSE: DWDP) is expected to report its most recent quarterly results before regular trading begins on Thursday. The consensus analyst estimates are $1.10 in EPS and revenue of $21.42 billion. Shares of DowDuPont were at $64.32 on Fridays close. The consensus price target is $82.80, and the 52-week range is $59.29 to $77.08.

ALSO READ: Alibaba, CVS, Tesla and Other Earnings to Watch For This Week